Cargando…

New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease

Background and Aims: Drug-induced steatosis is a major reason for drug failure in clinical trials and post-marketing withdrawal; and therefore, predictive biomarkers are essential. These could be particularly relevant in non-alcoholic fatty liver disease (NAFLD), where most patients show features of...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Riera, Mireia, Conde, Isabel, Tolosa, Laia, Zaragoza, Ángela, Castell, José V., Gómez-Lechón, María J., Jover, Ramiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5263149/ https://www.ncbi.nlm.nih.gov/pubmed/28179883 http://dx.doi.org/10.3389/fphar.2017.00003

Ejemplares similares

Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers
por: López-Riera, Mireia, et al.
Publicado: (2018)

Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat
por: Quintás, Guillermo, et al.
Publicado: (2022)

Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury
por: Tolosa, Laia, et al.
Publicado: (2017)

Foxa1 Reduces Lipid Accumulation in Human Hepatocytes and Is Down-Regulated in Nonalcoholic Fatty Liver
por: Moya, Marta, et al.
Publicado: (2012)

Development of Prediction Models for Drug-Induced Cholestasis, Cirrhosis, Hepatitis, and Steatosis Based on Drug and Drug Metabolite Structures
por: Shin, Hyun Kil, et al.
Publicado: (2020)

The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
por: Yu, Siyu, et al.
Publicado: (2021)

MicroRNA as an Important Target for Anticancer Drug Development
por: Fu, Zhiwen, et al.
Publicado: (2021)

Dietary Macronutrient Composition Determines the Contribution of DGAT1 to Alcoholic Steatosis
por: Huang, Li‐Shin, et al.
Publicado: (2018)

Development of a novel human triculture model of non-alcoholic fatty liver disease and identification of berberine as ameliorating steatosis, oxidative stress and fibrosis
por: Rafiei, Hossein, et al.
Publicado: (2023)

Induced pluripotent stem cells for the treatment of liver diseases: challenges and perspectives from a clinical viewpoint
por: Pareja, Eugenia, et al.
Publicado: (2020)

The assessment of the potential hepatotoxicity of new drugs by in vitro metabolomics
por: Quintás, Guillermo, et al.
Publicado: (2023)

miR-203 Inhibits Alcohol-Induced Hepatic Steatosis by Targeting Lipin1
por: Cheng, Xiao-Yu, et al.
Publicado: (2018)

Alcohol Abstinence Rescues Hepatic Steatosis and Liver Injury via Improving Metabolic Reprogramming in Chronic Alcohol-Fed Mice
por: Pi, Aiwen, et al.
Publicado: (2021)

Baicalein Prevents Fructose-Induced Hepatic Steatosis in Rats: In the Regulation of Fatty Acid De Novo Synthesis, Fatty Acid Elongation and Fatty Acid Oxidation
por: Li, Pan, et al.
Publicado: (2022)

Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes
por: Benson, Eric A., et al.
Publicado: (2016)

Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice
por: Zhang, Dan, et al.
Publicado: (2022)

Ginsenoside Rb1 Alleviates Alcohol-Induced Liver Injury by Inhibiting Steatosis, Oxidative Stress, and Inflammation
por: Lai, Yuqi, et al.
Publicado: (2021)

Nicotinic receptor modulation to treat alcohol and drug dependence
por: Rahman, Shafiqur, et al.
Publicado: (2015)

Hepatic Proteomic Changes and Sirt1/AMPK Signaling Activation by Oxymatrine Treatment in Rats With Non-alcoholic Steatosis
por: Xu, Hong, et al.
Publicado: (2020)

Lipophagy and Alcohol-Induced Fatty Liver
por: Yang, Li, et al.
Publicado: (2019)

Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
por: Declercq, Lieven D., et al.
Publicado: (2016)

Hepatoprotective effect of botanical drug formula on high-fat diet-induced non-alcoholic fatty liver disease by inhibiting lipogenesis and promoting anti-oxidation
por: Ning, De-Shan, et al.
Publicado: (2022)

Potential Drug-Drug Interactions in Patients With Urinary Tract Infections: A Contributing Factor in Patient and Medication Safety
por: Noor, Sidra, et al.
Publicado: (2019)

Platelets in Non-alcoholic Fatty Liver Disease
por: Dalbeni, Andrea, et al.
Publicado: (2022)

P-Hydroxyacetophenone Ameliorates Alcohol-Induced Steatosis and Oxidative Stress via the NF-κB Signaling Pathway in Zebrafish and Hepatocytes
por: Huang, Sha, et al.
Publicado: (2020)

Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy
por: Pulakat, Lakshmi, et al.
Publicado: (2020)

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review
por: Loren, Pía, et al.
Publicado: (2022)

miR-378b Regulates Insulin Sensitivity by Targeting Insulin Receptor and p110α in Alcohol-Induced Hepatic Steatosis
por: Li, Yuan-yuan, et al.
Publicado: (2020)

Transplantation of hESC-derived hepatocytes protects mice from liver injury
por: Tolosa, Laia, et al.
Publicado: (2015)

The 5-HT7 receptor as a potential target for treating drug and alcohol abuse
por: Hauser, Sheketha R., et al.
Publicado: (2015)

Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
por: Fischler, Pascal Valentin, et al.
Publicado: (2022)

Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
por: Fu, Yajie, et al.
Publicado: (2022)

Protective Effect of Patchouli Alcohol Against High-Fat Diet Induced Hepatic Steatosis by Alleviating Endoplasmic Reticulum Stress and Regulating VLDL Metabolism in Rats
por: Wu, Xue, et al.
Publicado: (2019)

Kaempferol Alleviates Steatosis and Inflammation During Early Non-Alcoholic Steatohepatitis Associated With Liver X Receptor α-Lysophosphatidylcholine Acyltransferase 3 Signaling Pathway
por: Xiang, Hongjiao, et al.
Publicado: (2021)

The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against‐Non-Alcoholic Steatohepatitis
por: Hong, Wei, et al.
Publicado: (2020)

High-Content Screening for the Detection of Drug-Induced Oxidative Stress in Liver Cells
por: Donato, María Teresa, et al.
Publicado: (2021)

Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
por: Chandrasekharan, Karthik, et al.
Publicado: (2020)

Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study
por: Létinier, Louis, et al.
Publicado: (2019)

Quantitative proteomics reveals Polygonum perfoliatum L. ameliorates hepatic steatosis by promoting PPARs/CPT1A/CPT2-mediated fatty acid β-oxidation
por: Liu, Guanjie, et al.
Publicado: (2023)

Editorial: Drug-drug interactions in pharmacology
por: Pichini, Simona, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_li5vsj60if3th2qft2de4nvmnh